Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
about
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapySerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsBNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculographyCancer drug related cardiotoxicity during breast cancer treatment.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic rCardiovascular disease after cancer therapy.Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclinesAnthracycline cardiotoxicity.Roadmap for biomarkers of cancer therapy cardiotoxicity.Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast CancerEvaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.Cardiotoxicity Following Cancer Treatment.Biological drugs: classic adverse effects and new clinical evidences.Cancer drugs and the heart: importance and management.Using cardiac biomarkers and treating cardiotoxicity in cancer.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship.Cardiomyopathy associated with cancer therapy.Advanced heart failure due to cancer therapy.Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.Anthracycline-Induced Cardiomyopathy in Adults.Identifying cancer patients at risk for cardiotoxicity.Heart failure and chemotherapeutic agents.Alternative Biomarkers for Combined Biology.Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice.Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation?Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.Cardiac complications of chemotherapy: role of biomarkers.
P2860
Q26743433-E701F578-3B5A-409B-A344-D9D835070C0BQ27007849-E151A4E9-E4C6-4359-BF0A-92BE11E9FCCEQ27027354-D13425F7-669B-43D2-AF04-D84B1AB7B27CQ28087776-047244C5-DCE4-4E3D-BC4B-227DBE4438D8Q28538548-F43BA381-60CF-45E2-A914-4F46072F630CQ30251498-5D84CDDF-70A0-4130-9FF0-0941B0BBB313Q30439608-E1798565-8E52-4ABB-88A5-77DACBA1BCEBQ34466688-D30164E1-0822-40E4-82E2-6C1AB1BBB278Q34560383-390167D2-5973-48F2-ADF9-04E2035E22A3Q34604429-DF83A3C7-0CE8-4B5F-8756-BF4EA930292BQ36416745-E1F63397-D5D2-4EA5-808C-D36B7A5C43EEQ36624983-D4193673-2795-4E20-A252-892D27850905Q36626934-FEEA088A-E76A-44CB-A4E4-28AE6B778D5FQ36788268-78783EB2-077D-4611-9588-DC43C5E384BAQ36836161-A68678D2-D3E8-4921-B662-5775EF826FEAQ36887091-19717BB7-79AD-41CA-A456-8E5390FE295DQ37100862-0037A011-876E-41FC-9872-4F5EB894C0F4Q37663263-F1D6BA11-9557-4A30-878C-D20466F533B2Q38015746-15587E63-F30C-4A20-BFF0-02E47B923EB9Q38025824-B3E47780-9901-4A86-8882-DA500152991AQ38069202-01F5836A-A6DC-4F58-9D07-16763B77039EQ38166071-BA55DFFE-ED93-4CDE-A70C-E076E4471E16Q38231301-2EB04D27-7CCC-4B19-AE89-986840EB93FCQ38242641-C4B61E3B-B555-4776-B203-F34CECC8F625Q38357704-01ACE962-ADF4-4470-8547-0B28DC6EDA7CQ38416816-8A2EB4C8-9246-4146-9F73-F006DB908EC2Q38542462-91C6BE86-1BE7-42B0-A421-20A6F5B73A1BQ38551772-091A1005-3E62-40F0-843A-BC00F1D02338Q38559133-E311051A-715D-4E59-8B6A-2D1C91002D93Q38747992-2101207B-8E62-4DDD-BBDD-688F623422B4Q44918082-462CAFB7-0A57-446A-AB23-8EA3B74BECBFQ45073135-7E67DFFC-DD4C-4B1E-B546-8026A14BFC68Q46717362-4A86105B-0F68-462B-BB6B-8F7AC53D69C3Q46772677-17655EE0-B34F-4825-9A6B-A1CFD9E45A64Q48244270-15F55FF4-15A5-4150-A626-F7CD07DDA72AQ48402822-96D6E06E-94E4-413D-BA06-B942D83CAE76Q48466932-475CE996-BE6B-4375-B504-8BE5043C5430Q48495062-3FCF454B-1CE3-4CC5-A61C-59F61DE22DA5Q49163835-CCD8E951-140B-43EF-9810-4B4B3ECFF801Q51739297-B7942940-C474-4468-93C5-A67B8B125723
P2860
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@en
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@nl
type
label
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@en
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@nl
prefLabel
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@en
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@nl
P2093
P2860
P50
P1476
Natriuretic peptides in the mo ...... ventricular ejection fraction.
@en
P2093
Birger Hesse
Erling Bjerregaard Pedersen
Kaare Troels Jensen
Ulrik Abildgaard
P2860
P356
10.1016/J.EJHEART.2004.03.009
P577
2005-01-01T00:00:00Z